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Abstract 
Background: Methotrexate is an important chemotherapeutic drug widely known as an inhibitor of dihydrofolate 
reductase (DHFR) which inhibits the reduction of folic acid. DHFR-mediated effects are apparently responsible for 
its primary antineoplastic action. However, other non-DHFR-mediated effects of methotrexate have been recently 
discovered, which might be very useful in the development of new strategies for the treatment of pediatric malignan-
cies. The principal goal of this study was to analyze the possible impact of clinically achievable methotrexate levels on 
cell proliferation, mechanisms of epigenetic regulation (DNA methylation and histone acetylation), induced differen-
tiation and the expression of differentiation-related genes in six osteosarcoma cell lines.
Methods: The Saos-2 reference cell line and five other patient-derived osteosarcoma cell lines were chosen for this 
study. The MTT assay was used to assess cell proliferation, DNA methylation and histone acetylation were detected 
using ELISA, and western blotting was used for a detailed analysis of histone acetylation. The expression of differenti-
ation-related genes was quantified using RT-qPCR and the course of cell differentiation was evaluated using Alizarin 
Red S staining, which detects the level of extracellular matrix mineralization.
Results: Methotrexate significantly decreased the proliferation of Saos-2 cells exclusively, suggesting that this 
reference cell line was sensitive to the DHFR-mediated effects of methotrexate. In contrast, other results indicated 
non-DHFR-mediated effects in patient-derived cell lines. Methotrexate-induced DNA demethylation was detected in 
almost all of them; methotrexate was able to lower the level of 5-methylcytosine in treated cells, and this effect was 
similar to the effect of 5-aza-2′-deoxycytidine. Furthermore, methotrexate increased the level of acetylated histone 
H3 in the OSA-06 cell line. Methotrexate also enhanced all-trans retinoic acid-induced cell differentiation in three 
patient-derived osteosarcoma cell lines, and the modulation of expression of the differentiation-related genes was 
also shown.
Conclusions: Overall non-DHFR-mediated effects of methotrexate were detected in the patient-derived osteosar-
coma cell lines. Methotrexate acts as an epigenetic modifier and has a potential impact on cell differentiation and the 
expression of related genes. Furthermore, the combination of methotrexate and all-trans retinoic acid can be effective 
as a differentiation therapy for osteosarcoma.
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Background
Methotrexate (MTX; amethopterin; 4-amino-10-methyl-
folic acid), a structural analogue of folic acid, is a chemo-
therapeutic drug which is still very frequently used as a 
treatment of osteosarcomas—the most common primary 
malignant bone tumors affecting both children and adults 
[1]. MTX has been included in therapeutic protocols for 
many years, but its dosage and administration schedules 
are still being optimized [2, 3].
MTX enters the cell through an active transport mech-
anism and by facilitated diffusion, and once inside, it is 
converted into polyglutamate MTX by folylpolyglutamyl 
synthase [4–6]. Polyglutamate MTX reversibly inhibits 
dihydrofolate reductase (DHFR) but also inhibits other 
enzymes, for example, phosphoribosylaminoimidazole-
carboxamide formyltransferase (AICAR transformylase) 
or thymidylate synthase (TS). Inhibition of DHFR affects 
the reduction of folic acid and consequently leads to a 
lack of 5,10-methylenetetrahydrofolate, which is used as a 
coenzyme in the biosynthesis of thymidine. Moreover, TS 
is directly blocked by MTX and by unmetabolized dihy-
drofolate. Purine precursor biosynthesis is also affected 
by the deficiency of another folate co-factor, 10-for-
myltetrahydrofolate and by MTX inhibition of AICAR 
transformylase. The inhibition of dTMP and purine syn-
thesis causes MTX-induced cell death [7].
Although MTX is able to inhibit proliferation and/
or induce apoptosis in neoplastic cells, there is also evi-
dence that it induces differentiation. MTX was able to 
induce differentiation in colon cancer cells primarily due 
to the intracellular depletion of purines [8], in immature 
and undifferentiated monocytic cells [9] and in rat cho-
riocarcinoma cells [10]. Overall, cytostatic, cytotoxic and 
differentiation effects are mediated by the functional sup-
pression of DHFR and nucleotide biosynthesis.
In addition to the cytostatic and differentiation effects 
of MTX, non-DHFR-mediated effects concerning the 
modulation of important epigenetics determinants have 
also been described, such as DNA methylation [11] and 
histone acetylation [12]. The mechanism of the methyla-
tion of biomolecules is not always clear because both the 
DHFR- and non-DHFR-mediated effects of MTX can 
contribute to the decreased methylation of molecules 
in the cell. On one hand, inhibition of folate metabo-
lism as described above can affect the intracellular lev-
els of 5-methyltetrahydrofolate which transfers methyl 
groups to methionine synthase to generate methionine 
from homocysteine [13]. Methionine can be utilized for 
the synthesis of the universal methyl donor S-adenosyl-
methionine (SAM) which plays a pivotal role in the gen-
eration of 5-methylcytosine. On the other hand, MTX 
directly inhibits methionine adenosyltransferase (MAT) 
mRNA expression and reduces MAT protein levels which 
significantly decreases MAT activity [13]. This is of par-
ticular importance because MAT is a key enzyme that 
catalyzes the only reaction that produces SAM. Moreo-
ver, MAT expression and activity can be inhibited even 
by a very low concentration of MTX (50 nmol). Regarding 
histone acetylation, molecular modeling suggested that 
MTX is a potential histone deacetylase inhibitor due to its 
shared structural similarity with some histone deacetylase 
inhibitors (e.g., butyrate or trichostatin A), and it has been 
shown that MTX directly inhibits histone deacetylase 
activity and induces histone H3 acetylation in vitro [12].
It has been shown that the induced differentiation of 
tumor cells is a promising strategy in cancer therapy [14]. 
Especially, all-trans retinoic acid (ATRA) and its deriva-
tives are widely used differentiation drugs that can induce 
the osteogenic differentiation of osteosarcoma cells [15]. 
The main disadvantage of retinoid usage is the occur-
rence of resistance [16]. On one hand, DNA methylation 
has a significant role in preventing normal differentiation 
in pediatric cancers [17], and on the other hand, DNA 
demethylation can contribute to cell differentiation; for 
example, the expression of the retinoic acid receptor beta 
(RARB) can be activated by the hypomethylating action 
of 5-aza-2′-deoxycytidine [18]. Histones are involved in 
the regulation of chromatin structure and gene expres-
sion as well as in DNA methylation. Histone H3 acety-
lation is also associated with gene expression. Therefore, 
due to its impact on nucleotide synthesis, as well as DNA 
methylation and histone acetylation, MTX could modu-
late gene expression and enhance the ATRA-induced dif-
ferentiation of osteosarcoma cells.
In the present study, we focused on MTX action in six 
cell lines derived from osteosarcomas. The MTX effect 
on DNA methylation was compared with the effect of 
the known DNA methyltransferase inhibitor 5-aza-2′-
deoxycytidine (5AZA), and the accumulation of acetyl 
histone H3 after MTX treatment was compared with 
the effects of the known histone deacetylase inhibitors 
sodium butyrate (BUT) and sodium valproate (VAL). 
We also studied the MTX impact on the expression of 
selected genes related to cell differentiation, and we 
assessed cell differentiation induced by MTX, ATRA or 
a combination of the two. Therefore, our work repre-
sents the first complex study of the non-DHFR-mediated 
effects of MTX in cancer cells with special attention to 
the modulation of epigenetic information in terms of 
DNA methylation and histone acetylation.
Results
Our results showed that the non-DHFR mediated effects 
of MTX were detectable, especially in patient-derived cell 
lines and that MTX act as an epigenetic modifier with an 
impact both on DNA demethylation and the accumulation 
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of acetylated histones. Moreover, the combination of 
MTX and ATRA may represent a new therapeutic option 
in the differentiation therapy of osteosarcoma.
Patient‑derived cell lines are more resistant to MTX 
than Saos‑2 cell line
Using the MTT assay, an analysis of proliferation activity 
was performed on day 6 of MTX treatment at concentra-
tions from 0.0001 to 100  μM. Significant differences in 
the sensitivity of cell lines used in this study (Fig. 1) were 
noted. On one hand, MTX showed a strong cytotoxic 
effect on the Saos-2 reference cell line at concentrations 
ranging from 0.1 to 100 μM. On the other hand, all five 
patient-derived OSA cell lines were significantly more 
resistant to MTX action, and even the very high concen-
tration of 100 μM was not sufficient to reach the IC50.
MTX induces DNA demethylation in a majority 
of osteosarcoma cell lines
Despite the mild effect of MTX on cell proliferation, we 
continued to study the non-DHFR-mediated effects of 
MTX on DNA methylation. Significant DNA demethyla-
tion was observed in Saos-2, OSA-03, OSA-05, OSA-06 
and OSA-08 cells at day 3 of the MTX treatment, espe-
cially at a concentration of 40  μM (Fig.  2). The MTX-
induced DNA demethylation was most obvious in the 
OSA-06 cells–the level of 5-methylcytosine decreased 
to 86  % at 1  μM MTX and to 76  % at 40  μM MTX in 
comparison with untreated control cells. As expected, 
the positive control 5AZA induced DNA demethylation 
in Saos-2, OSA-03, OSA-05, OSA-06 and OSA-08. Sur-
prisingly in Saos-2, OSA-03, OSA-05 and OSA-06 cells, 
40  μM MTX induced DNA demethylation comparable 
to the effect of 5AZA at the same concentration. We did 
not observe any changes in DNA methylation in OSA-02 
cells.
MTX increases the global histone H3 acetylation in OSA‑06 
cells
Given that MTX is a possible histone deacetylase inhibi-
tor, we determined whether MTX could increase histone 
H3 acetylation. Treatment with BUT and VAL served as a 
positive controls and, in some cases, treated cells showed 
the significant accumulation of acetylated histone H3 in 
comparison with an untreated control (Fig.  3). We did 
not detect an increase in the global acetylation of histone 
H3 at day 3 of the MTX treatment in Saos-2, OSA-02, 
OSA-03, OSA-05 and OSA-08 cells (Fig.  3a–d, f ); how-
ever, we observed an increase of histone H3 acetylation 
in OSA-06 cells (Fig. 3e), and therefore, this cell line was 
further analyzed using western blotting. Cells were incu-
bated with MTX, VAL or BUT, and the nuclear protein 
fractions were harvested and immunoblotted on day 3 of 
the treatment (Fig. 4). Our data demonstrated that MTX 
increased histone H3 acetylation in OSA-06 cells in a 
concentration-dependent manner.
MTX alters the expression of differentiation‑related genes
To further explore the importance of epigenetic altera-
tions induced by MTX, we decided to assess the MTX 
impact on the expression of selected genes involved in 
cell differentiation. The expression of genes encoding 
known markers of osteogenic differentiation (COLLI, 
ALPL) as well as genes involved in ATRA metabolism 
and the regulation of gene expression were evaluated 
using RT-qPCR on day 3 of MTX treatment at con-
centrations of 1 μM and 40 μM (Fig. 5). In Saos-2 cells, 
we observed a significant increase in the expression of 
RARA, CRBP1 and CRABP2. Interestingly, the expres-
sion of CRABP2 was increased approximately ten-fold, 
but the expression of RARB and ALPL was significantly 
lower (Fig. 5a). In OSA-02 cells, MTX at both concentra-
tions significantly increased the expression of RARA and 
also the expression of COLLI at 40 µM. In contrast, the 
expression of CRBP1 was at a very low level (Fig. 5b). In 
OSA-03 cells, COLLI expression was significantly higher 
after treatment with 40 µM MTX, but the same concen-
tration of MTX significantly decreased the expression of 
CRABP2 and ALPL (Fig. 5c). In OSA-05 cells, 1 µM MTX 
significantly increased the expression of RARA, RARB 
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Fig. 1 Proliferation activity of osteosarcoma cell lines after treatment 
with MTX. Proliferation activity was measured using MTT assay at day 
6 of incubation with various concentrations of MTX and compared 
with those of untreated control cells. Untreated controls were set 
as 100 %. The data represent the mean ± SD. Experiments were 
repeated three times in duplicates. **P < 0.01, indicates significant 
differences from the respective cell lines
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decreased the expression of CRABP2 only (Fig.  5e). In 
OSA-08 cells, the expression of RARA and CRBP1 was 
significantly increased after MTX treatment (Fig. 5f ).
Osteogenic differentiation is enhanced by combined 
treatment with MTX and ATRA
As indicated by the previous analyses, MTX treatment 
significantly increased the expression of some genes 
involved in ATRA metabolism and the regulation of gene 
expression. This observation led us to explore whether 
MTX could enhance ATRA-induced differentiation. After 
21  days of cultivation, all cell lines formed calcium-pos-
itive nodules in control cell populations as well as under 
all experimental conditions. In the Saos-2 cell line, MTX 
significantly enhanced the extent of this mineralization 
(Fig. 6a), but MTX-induced mineralization was less appar-
ent in all five OSA cell lines (Fig. 6b–f). ATRA significantly 







































































































































Fig. 2 Changes in DNA methylation in osteosarcoma cell lines after treatment with MTX. Levels of 5-methylcytosine in Saos-2 (a), OSA-02 (b), OSA-
03 (c), OSA-05 (d), OSA-06 (e) and OSA-08 (f) cells as measured using an ELISA assay at day 3 of incubation. The levels of 5-methylcytosine are pre-
sented as a percentage change compared to the levels found in untreated control cells. Untreated controls were set as 100 %. The data represent 
the mean ± SD. Experiments were repeated three times. *P < 0.05, **P < 0.01, indicate significant differences from the respective control groups
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similar to MTX. In all OSA cell lines ATRA was always 
more effective in enhancing mineralization than MTX and 
in all cases significantly enhanced the extent of the min-
eralization. The combination of ATRA (0.1 or 1 μM) and 
MTX (1 or 40  μM) did not have an additional effect on 
the amount of calcium sediments in Saos-2, OSA-02 and 
OSA-08 cell lines. Interestingly, in the OSA-03, OSA-05 
and OSA-06 cell lines, a combined treatment with ATRA 
and MTX significantly enhanced the mineralization in 
comparison with the untreated control by 21–28  %. The 
greatest increase in mineralization with the combined 
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Fig. 3 Changes in global histone H3 acetylation in osteosarcoma cell lines after treatment with MTX. Levels of global histone H3 acetylation in 
Saos-2 (a), OSA-02 (b), OSA-03 (c), OSA-05 (d), OSA-06 (e) and OSA-08 (f) cells as measured using ELISA assay at day 3 of incubation. The levels of 
global histone H3 acetylation are presented as a percentage change compared to the levels found in untreated control cells. Untreated controls 
were set as 100 %. The data represent the mean ± SD. Experiments were repeated three times. *P < 0.05, **P < 0.01, indicate significant differences 
from the respective control groups
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Discussion
For decades, MTX was a commonly used therapy in 
osteosarcoma patients [19]. MTX interferes with folate 
metabolism but its other antineoplastic effects are still 
being discovered, and these effects can be helpful in the 
development of new strategies for osteosarcoma treat-
ment [20]. The principal goals of this study were to ana-
lyze the non-DHFR-mediated effects of MTX in cell lines 
derived from osteosarcomas and to determine whether 
MTX acts as an epigenetic modifier in terms of DNA 
demethylation, histone acetylation, subsequent changes 
in gene expression and induced cell differentiation. The 
Saos-2 osteosarcoma cell line was chosen as the refer-
ence cell line for this study, and it was compared with five 
other cell lines that were derived in our laboratory from 
biopsy samples taken from patients suffering with osteo-
sarcoma [21].
The MTT assay indicated that Saos-2 cells were very 
sensitive to MTX treatment, which showed a strong 
cytotoxic effect in these cells at 0.1  μM. This observa-
tion is in full accordance with our previous study [22] 
and with results obtained by other research groups 
studying the sensitivity of Saos-2 cells to MTX [23]. All 
five OSA cell lines, which were derived from diagnostic 
biopsies of primary tumors without any previous neo-
adjuvant chemotherapy, were significantly more resist-
ant to the DHFR-mediated effect of MTX than Saos-2 
cell line. The resistance of the OSA cell lines is surpris-
ing when we consider that 40  μM MTX is comparable 
with the peak of the MTX plasma concentration achieved 
during high dose-MTX treatments of pediatric hemato-
logical malignancies. In osteosarcomas, the peak MTX 
levels are approximately 1000  μM but rapidly decline 
within hours. Altogether, these results show that lower 
levels of MTX could not fully inhibit DHFR and nucleo-
tide biosynthesis in all OSA cell lines despite prolonged 
exposure [24]. Furthermore, all OSA cells showed a low 
doubling time in comparison with Saos-2 cells that could 
diminish the proliferation-dependent cytotoxicity of 
MTX [25]. Other possible mechanisms of MTX resist-
ance are an augmented drug efflux, impaired intracellular 
polyglutamation or alterations in the activity of target 
enzymes [6].
Because we did not observe any profound negative 
DHFR-mediated impact of MTX on cell proliferation in 
almost all of the cell lines included in this study, we con-
tinued with experiments that focused on other possible 
non-DHFR-mediated effects of MTX on osteosarcoma 
cells. MTX decreases the concentration of 5-methyltet-
rahydrofolate [26, 27] and reduces MAT expression and 
activity [13], which can further affect methylation in 
treated cells. 5-methyltetrahydrofolate and homocyst-
eine are two important molecules in methionine bio-
synthesis [28]. Methionine reacts with ATP, and SAM 
is formed as a product. This key reaction is catalyzed by 
MAT. A methyl group from SAM is enzymatically trans-
ferred to the 5-position of cytosine to generate 5-methyl-
cytosine in genomic DNA. Our data demonstrate that 
MTX significantly decreased 5-methylcytosine levels in 
genomic DNA and induce global genomic DNA dem-
ethylation. Surprisingly, significant DNA demethylation 
was observed in almost all of the cell lines used in our 
experiments.
Due to the similar structure of MTX and known his-
tone deacetylase inhibitors, e.g., butyrate and trichosta-
tin A, MTX can inhibit histone deacetylase activity and 
induce histone H3 acetylation [12]. Nevertheless, the five 
cell lines in our study including Saos-2 showed a poor 
response to MTX in this aspect. Only the OSA-06 cell 
line has a higher level of acetyl histone H3 after MTX 
treatment. Therefore, OSA-06 cells were further analyzed 
by western blotting to confirm this effect and the results 
showed that MTX increased the level of acetylated his-
tone H3 in this cell line. As expected, most of cell lines 
showed a significant increase in the amount of acetylated 
histone H3 after treatment with BUT or VAL.
In contrast, MTX changed the methylation status of 
DNA in almost all of the studied cell lines. This finding 
led us to explore two important issues: (i) alterations of 
expression of the selected genes in MTX-treated cells and 
(ii) effect of MTX on differentiation in osteosarcoma cells 
after a combined treatment with ATRA because ATRA is 
a widely used inducer of differentiation in osteosarcoma 
cells [15, 29, 30].
Both of these aspects are important and mutually inter-
connected. Inducing differentiation of tumor cells by reti-
noids seems to be a very promising strategy, but it can 
be complicated by the resistance of tumor cells [16, 31–
33]. The regulation of cell differentiation by retinoids is 
mediated by two types of nuclear receptors: retinoic acid 
receptors (RAR) and retinoid X receptors (RXR). DNA 
methylation patterns could affect the normal course of 
the expression of genes involved in cell differentiation 








Fig. 4 Effect of MTX on histone H3 acetylation in OSA-06 cells. Cells 
were incubated with 1 or 40 μM MTX, VAL or BUT. At day 3, nuclear 
protein extracts were harvested and immunoblotted by anti-acetyl-
histone H3 antibody. PCNA served as a loading control

































































































































Fig. 5 Changes in expression of differentiation-related genes in osteosarcoma cell lines after treatment with MTX. The relative expression of 
selected genes in Saos-2 (a), OSA-02 (b), OSA-03 (c), OSA-05 (d), OSA-06 (e) and OSA-08 (f) cells measured using RT-qPCR at day 3 of incubation 
with 1 μM MTX (1MTX) or with 40 μM MTX (40MTX). The levels of relative gene expression are presented as fold changes compared to the levels 
detected in control samples. The data represent the mean ± SD. Experiments were repeated three times. *P < 0.05, **P < 0.01, indicate significant 
differences from the respective control groups
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cancer cell lines and treatment of these cell lines with a 
demethylating agent can restore inducibility of RARB by 
ATRA [35]. Other studies have demonstrated that the 
RARB promoter is hypermethylated in colorectal and 
lung carcinomas and that this methylation could account 
for the RARB downregulation [18, 36].
At first, we studied whether MTX could modulate the 
expression of genes involved in retinoid/ATRA metabo-
lism and signaling and whether MTX alone could induce 
differentiation in osteosarcoma cells. After treatment 
with MTX, we observed that the RARA was significantly 
highly expressed in Saos-2 and OSA-02 cells. Another 
interesting observation was the significantly increased 
expression of CRABP2 in Saos-2 cells. CRABP2 encodes 
the cytosol-to-nuclear shuttling protein, which facili-
tates the binding of retinoic acid to its receptor and the 
transfer of this complex to the nucleus. Furthermore, the 
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Fig. 6 Changes in matrix mineralization in osteosarcoma cell lines after treatment with MTX. Saos-2 (a), OSA-02 (b), OSA-03 (c), OSA-05 (d), OSA-06 
(e) and OSA-08 (f) cell lines treated with MTX and/or ATRA were measured using staining with Alizarin Red S at day 21 of incubation. The extent of 
mineralization is presented as a percentage change compared to the levels found in untreated control cells. Untreated controls were set as 100 %. 
The data represent the mean ± SD. Experiments were repeated three times. *P < 0.05, **P < 0.01, indicate significant differences from the respective 
control groups
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involved in the transport of retinol from liver storage site 
to the peripheral tissue was also significantly elevated in 
Saos-2 cells as well as in OSA-08 cells.
Regarding osteogenic differentiation, we examined the 
expression of known osteogenic differentiation markers, 
i.e., collagen type I (COLLI) and alkaline phosphatase 
(ALPL) [30]. Increase in COLLI expression is typical in 
the early stages of differentiation whereas levels of ALPL 
usually increase during the process of mineralization, 
i.e., during the late stages of induced differentiation [37]. 
Nevertheless, we did not observe a marked increase in 
expression of these markers.
Because the expression of some differentiation-related 
genes was modulated after 3 days of MTX treatment, we 
decided to evaluate a long time course of osteogenic dif-
ferentiation using mineralization measured by Alizarin 
Red S staining [30]. MTX and ATRA alone increased the 
extent of matrix mineralization in all cell lines but ATRA 
was apparently more effective. Interestingly, MTX alone 
was able to induce cell differentiation effectively in the 
Saos-2 cell line; this finding is in accordance with previ-
ously published results on choriocarcinoma cells [38]. 
Our data also demonstrated that a combined treatment 
with ATRA and MTX enhanced matrix mineralization 
most greatly in the OSA-03, OSA-05 and OSA-06 cell 
lines, so the combined administration of MTX and reti-
noids could be effective in differentiation therapy of some 
osteosarcomas.
Conclusions
To summarize, our study represents the first complex 
analysis of the non-DHFR-mediated effects of MTX on 
cell lines derived from osteosarcomas. We showed that 
MTX treatment significantly decreased the prolifera-
tion activity in the Saos-2 reference cell line, but all five 
patient-derived OSA cell lines were much less sensitive 
to MTX action. These results suggest that all OSA cell 
lines were not sensitive to the DHFR-mediated effects 
of MTX at concentrations used. More importantly, 
our results provide the evidence for non-DHFR-medi-
ated effects of MTX in both Saos-2 and OSA cell lines. 
MTX could act as an epigenetic modifier because (1) it 
induced significant DNA demethylation in almost all of 
the studied osteosarcoma cells and (2) it increased the 
global acetylation of histone H3 in OSA-06 cells. Our 
findings also demonstrated the modulation of the expres-
sion of differentiation-related genes by MTX at certain 
concentrations. The most important result of our study 
showed that ATRA-induced cell differentiation might be 
enhanced by the combined treatment of cells with MTX; 
this implies new possibilities in administration of these 
drugs in clinical practice.
Methods
Cell culture
The Saos-2 cell line (No. HTB-85) was purchased from 
the American Type Culture Collection (Manassas, VA, 
USA). The OSA-02, OSA-03, OSA-05, OSA-06 and OSA-
08 cell lines were derived in our laboratory from tumor 
samples obtained from patients surgically treated for 
osteosarcoma as previously described [21]. A description 
of the cell lines included in this study and their responses 
to MTX is provided in Table 1. The Research Ethics Com-
mittee of the School of Medicine (Masaryk University, 
Brno, Czech Republic) approved the study protocol and 
a written statement of informed consent was obtained 
from each patient or his/her legal guardian.
Cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10  % (Saos-2) 
or 20 % (OSA-02, OSA-03, OSA-05, OSA-06 and OSA-
08) fetal bovine serum, 100 IU/ml penicillin, 100 mg/ml 
streptomycin, and 2 mM glutamine (all purchased from 
GE Healthcare Europe GmbH, Freiburg, Germany). Cell 
culture was performed under standard conditions at 
37 °C in a humidified atmosphere containing 5 % CO2.
Chemicals
MTX (Sigma-Aldrich, St. Louis, MO, USA) was prepared 
as a stock solution at a concentration of 20 mM in 1 M 
NaOH (Sigma) and stored at −20  °C under light-free 
conditions. BUT and VAL (both from Sigma) were pre-
pared as stock solutions at concentrations of 50  mM in 
sterile PBS and 5AZA (Sigma) was prepared as a stock 
solution at a concentration of 1  mM in sterile PBS. All 
three stock solutions were prepared freshly for each use. 
ATRA (Sigma) was prepared as a stock solution at con-
centration of 100  mM in DMSO (Sigma) and stored at 
−20 °C under light-free conditions.
For the determination of proliferation activity, seven 
different concentrations of MTX ranging from 0.0001 
to 100  μM were tested. For all other experiments, con-
centrations of 1 and 40 μM MTX were used. 5AZA, VAL 
and BUT served as positive controls and were used at the 
same concentration as MTX, i.e., 1 and 40 μM.
In experiments on matrix mineralization, 1 μM ATRA 
was used as in previously published experiments con-
cerning the ATRA-induced differentiation of osteosar-
coma cells [30]. For the treatment of Saos-2 cells lower 
concentrations (i.e., 1 μM MTX and 0.1 μM ATRA) were 
used due to the previously reported sensitivity of these 
cells [30].
MTT assay
To evaluate cell proliferation, the MTT assay was used to 
detect the activity of mitochondrial dehydrogenases in 
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living cells. 96-well plates were seeded with 1 × 104 cells 
per well in 200 μl of culture medium, and the cells were 
allowed to adhere overnight. The medium was removed 
and fresh medium containing the selected concentra-
tions of chemicals described above or a control medium 
was added. The plates were incubated under standard 
conditions. To evaluate changes in cell proliferation, the 
medium was removed and replaced with 200 μl of fresh 
DMEM containing 3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide (MTT) at 0.5  mg per ml. 
The plates were then incubated at 37  °C for 2.5  h. The 
medium was carefully removed, and the formazan crys-
tals were dissolved in 200 μl of DMSO. The absorbance 
with a reference absorbance at 620  nm was measured 
at 570  nm using a Sunrise Absorbance Reader (Tecan, 
Männedorf, Switzerland).
DNA methylation analysis
Total DNA was extracted using a DNeasy Blood & Tis-
sue Kit (Qiagen, Hilden, Germany), and its concentra-
tion and purity was determined spectrophotometrically. 
Levels of 5-methylcytosine were detected using a 5-mC 
DNA ELISA Kit (Zymo Research Corporation, Irvine, 
CA, USA) according to the manufacturer’s instructions. 
The absorbance was measured at 450 nm with the Sun-
rise Absorbance Reader.
Global histone H3 acetylation
For the specific measurement of global histone H3 acety-
lation, an EpiQuik Global Histone H3 Acetylation Assay 
Kit (Epigentek Group Inc., Farmingdale, NY, USA) was 
used according to the manufacturer’s instructions. The 
absorbance was measured at 450  nm using the Sunrise 
Absorbance Reader.
RT‑qPCR
The relative expression levels of selected genes were 
studied using RT-qPCR. Total RNA was extracted using 
the GenElute™ Mammalian Total RNA Miniprep kit 
(Sigma), and its concentration and integrity was deter-
mined spectrophotometrically. For all samples, equal 
amounts of RNA (i.e., 25 ng of RNA per 1 μl of total reac-
tion volume) were reverse transcribed into cDNA using 
M-MLV (Top-Bio, Prague, Czech Republic). RT-qPCR 
was carried out in 10 μl using KAPA SYBR® FAST qPCR 
Kit (Kapa Biosystems, Wilmington, MA, USA) and ana-
lyzed using 7500 Fast Real-Time PCR System and 7500 
Software v. 2.0.6 (both Life Technologies, Carlsbad, CA, 
USA). Changes in the transcript levels were calculated 
using Cq values standardized to a housekeeping gene 
(HSP90AB1), used as an endogenous reference gene 
control. Primers used for retinoic acid receptor alpha 
(RARA), retinoic acid receptor beta (RARB), retinoid X 
receptor alpha (RXRA), retinol binding protein 1 (RBP1), 
cellular retinoic acid binding protein 2 (CRABP2), col-
lagen type I (COLL I), alkaline phosphatase (ALPL) and 
heat shock protein (HSP90AB1) are described in Table 2.
Table 1 Description of the cell lines and characterization of their responses to MTX
Gender: M male, F female; Age at the time of diagnosis: years; Tumor type: HGCC high grade conventional-chondroblastic, T teleangiectatic, O osteoblastic, N/A 
information not available; Time of biopsy: DG diagnostic, N/A information not available; Responses to MTX, i.e. DNA demethylation, histone H3 acetylation; enhanced 
matrix mineralization: Y yes, N no




Saos-2 F 11 N/A N/A Y N N
OSA-02 M 21 HGCC DG N N N
OSA-03 M 15 HGCC DG Y N Y
OSA-05 M 9 T DG Y N Y
OSA-06 F 16 O DG Y Y Y
OSA-08 M 10 O DG Y N N
Table 2 Sequences of the primers used for qPCR
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Western blot analysis
Nuclear protein extracts were harvested using NE-PER™ 
Nuclear and Cytoplasmic Extraction Reagents (Life Tech-
nologies, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Total proteins (15  μg) were loaded 
onto 10  % polyacrylamide gels, electrophoresed, and 
blotted on polyvinylidene difluoride membrane (Bio-
Rad Laboratories, Munich, Germany). The membranes 
were blocked with 5 % nonfat dry milk in PBS with 0.1 % 
Tween-20 (Sigma) and incubated overnight either with 
rabbit polyclonal anti-acetyl-Histone H3 (Ac-Lys9) (No. 
H9286, Sigma, dilution 1:1000) or with mouse monoclo-
nal anti-Proliferating Cell Nuclear Antigen (anti-PCNA) 
(No. P8825, clone PC10, Sigma, dilution 1:3000). Anti-
mouse IgG antibody peroxidase conjugate (No. A9917, 
Sigma, dilution 1:10,000) or anti-rabbit IgG HRP-linked 
antibody (No. 7074, Cell Signaling Technology, Danvers, 
MA, USA, dilution 1:2000) was used as the secondary 
antibodies. ECL-Plus detection was performed according 
to the manufacturer’s instructions (GE Healthcare, Little 
Chalfont, UK).
Alizarin Red S staining
Levels of extracellular matrix mineralization were evalu-
ated using Alizarin Red S staining, which detects cal-
cium compounds both in tissue sections and in  vitro. 
The cells were seeded onto 12-well plates at concentra-
tions of 1 × 104 (Saos-2 cell line) or 5 × 103 (all OSA cell 
lines) cells per well and were cultivated in the presence 
or absence of ATRA and/or MTX for 21 days. The culti-
vation medium with these substances was renewed every 
7  days. After 21  days of incubation, the medium was 
removed, the cells were washed with PBS and fixed with 
3  % paraformaldehyde in PBS at room temperature for 
20 min. Subsequently, the cells were incubated with 2 % 
Alizarin Red S (Sigma) at room temperature for 45 min. 
Thereafter, the cells were washed five times with deion-
ized water and then with 70 % ethanol for 30 s. Red Aliz-
arin dye was then dissolved via incubation with 100 mM 
cetylpyridinium chloride (Sigma) at 50 °C for 60 min. The 
absorbance was measured at 450 nm also using the Sun-
rise Absorbance Reader.
Statistical analysis
The quantitative data are shown as mean ± SD of three 
independent experiments. Data from MTT assays were 
analyzed using two-way ANOVA followed by the Scheffé 
post hoc test. P  <  0.01 was considered significant. The 
other data were analyzed using Student’s t test. P < 0.05 
(two-sides) were considered statistically significant.
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